[Use of finoptin in patients with non-insulin-dependent diabetes mellitus with concomitant essential hypertension].
The paper is devoted to a study of the time course of lipid metabolism, analysis of glucose tolerance, change in indices of immunoreactive insulin, glucagon and C-peptide before the start of verapamil therapy and 6 mos. after it during monotherapy with this drug. These parameters were investigated in the blood serum using biochemical methods and radioimmunoassays. A marked antihypertensive effect was achieved in patients suffering from noninsulin dependent diabetes mellitus with concomitant essential hypertension of the 2nd degree. No negative effect on the pancreatic hormone secretion was noted. Lipid transport indices were improved.
Belovalova
I M
IM
Mel'chinskaia
E N
EN
Starosel'tseva
L K
LK
D000328:Adult; D000368:Aged; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005934:Glucagon / Q000378:metabolism; D005951:Glucose Tolerance Test; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay; D014700:Verapamil / Q000627:therapeutic use*
D002096:C-Peptide; D007328:Insulin; D008055:Lipids; D005934:Glucagon; D014700:Verapamil
Primenenie finoptina u bol'nykh insulinnezavisimym sakharnym diabetom s soputstvuiushcheĭ gipertonicheskoĭ bolezn'iu.